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Abstract
The initiation of cellular programs is orchestrated by key transcription factors and chromatin
regulators that activate or inhibit target gene expression. To generate a compendium of chromatin
factors that establish the epigenetic code during developmental hematopoiesis, a large-scale
reverse genetic screen was conducted targeting orthologs of 425 human chromatin factors in
zebrafish. A set of chromatin regulators was identified that target different stages of primitive and
definitive blood formation, including factors not previously implicated in hematopoiesis. We
identified 15 factors that regulate development of primitive erythroid progenitors and 29 factors
that regulate development of definitive stem and progenitor cells. These chromatin factors are
associated with SWI/SNF and ISWI chromatin remodeling, SET1 methyltransferase, CBP/P300/
HBO1/NuA4 acetyltransferase, HDAC/NuRD deacetylase, and Polycomb repressive complexes.
Our work provides a comprehensive view of how specific chromatin factors and their associated
complexes play a major role in the establishment of hematopoietic cells in vivo.
The programs of gene expression required for maintenance and differentiation of cell types
are tightly regulated by a network of transcription factors and associated chromatin
modifying factors to facilitate or suppress gene expression. Epigenetic information consists
of chemical modifications to both cytosine bases in DNA and histone proteins that fold the
DNA into nucleosomes, as well as the repositioning, dissociation, and/or reconstitution of
entire nucleosomes1. Mouse knockout models and zebrafish mutants have been used to
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tinvestigate the role of chromatin factors in vertebrate development, but the majority of
chromatin factors have yet to be characterized2-5.
Hematopoiesis is guided by cell-specific transcriptional regulators and associated chromatin
factors that function to establish all mature blood cells6. This process is hallmarked by the
establishment of hematopoietic stem cells (HSCs) and depends on the function of
transcriptional regulators, Runx1, Scl, Lmo2, and chromatin factors, Mll and Bmi1, for stem
cell production, self-renewal, and survival. Additional factors coordinate the specialization
of HSCs into multilineage progenitors that generate differentiated cells of the peripheral
blood lineages6. Members of the Polycomb (PcG) family have previously been identified as
regulators of hematopoiesis. Bmi1 functions to positively regulate HSC proliferation by
limiting cell cycle regulator expression, and HSCs with Bmi1 deficiency show impaired
self-renewal capacity7. The Mi-2/NuRD complex regulates a set of HSC specific genes that
maintain the HSC pool in the bone marrow. De-repression of these genes in Mi-2beta
deficient HSCs exhausts the HSC pool8. Several chromatin factors have been identified as
leukemic translocation partners, underscoring the importance they have in normal
development. MLL is rearranged in the majority of infant leukemias with patients generally
having poor clinical outcomes9. Similarly, translocations of PRDM16, another SET family
member, is associated with a poor prognosis10. Both promote the development of normal
HSCs and leukemic stem cells 9,11.
To identify chromatin factors that function during developmental hematopoiesis, we have
undertaken a large-scale in vivo reverse genetic morpholino-based screen targeting zebrafish
orthologs of 425 human chromatin factors. The zebrafish provides a suitable platform for
rapid screening to assay the function of chromatin factors in hematopoiesis due to their high
fecundity, rapid development, evolutionary conservation, and ease in generating genetic
knockdowns. We have identified 44 factors that affect the development of primitive and
definitive blood, including 28 factors that have yet to be associated with hematopoiesis. We
have also characterized different developmental stages during which these factors function,
from the induction of stem and progenitor cells to differentiation into erythroid cells. By
incorporating protein interaction data, we predict the BAF/PBAF, ISWI, SET1, CBP/P300/
HBO1/NuA4, HDAC/NuRD, and PRC1/PRC2 complexes as required for blood
development. Taken together, our screen provides a valuable resource for elucidating the in
vivo network of chromatin regulators of hematopoietic development.
Results
A screen for chromatin regulators of developmental hematopoiesis
To identify the chromatin remodeling factors that function in developmental hematopoiesis,
we conducted a large-scale in vivo reverse genetic screen targeting chromatin factors (Fig.
1a). We designed antisense oligonucleotide morpholinos to knock down expression of 488
zebrafish orthologs of 425 human chromatin factors (Supplementary Table 1). Our gene list
included most of the known human factors containing chromatin binding, modifying, or
remodeling domains curated from several public databases: CREMOFAC, SMART domain
by NRDB, CDD at NCBI, Pfam, and ChromDB12-16. 488 orthologous genes in zebrafish
were identified by a reciprocal BLAST search of the unique human protein sequences into
the zebrafish genome. Only 26 human proteins lacked a zebrafish ortholog.
Morpholinos targeting each chromatin factor were injected into single cell embryos at three
concentrations. These doses typically give a range of phenotypes from a hypomorph to a
near complete knockdown for most mRNA products, similar to an allelic series. In some
cases, complete knockdown could not be achieved because of lower targeting efficiency or
embryonic lethality. Post-injection, embryos were collected at specific timepoints, using
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tboth standard morphological features of the whole embryo and hours post-fertilization (hpf)
to stage to minimize differences in embryonic development caused by the morpholino
injection17. The embryos were then assayed for hematopoietic defects by whole-mount in
situ hybridization (WISH). We conducted two screens simultaneously for primitive and
definitive blood formation. For the primitive screen, developing erythrocytes in the posterior
mesoderm of the embryo were assayed by β-globin e3 expression at the 16 somite stage (ss),
or 17 hpf (Fig. 1b)18. For the definitive screen, the establishment of hematopoietic stem and
progenitor cells (HSPCs) in the aorta, gonad, mesonephros region (AGM) was detected with
c-myb and runx1 expression at 36 hpf (Fig. 1c)19.
To establish the level of morpholino efficacy, the 21 splice blocking morpholinos targeting
the chromodomain (CHD) gene family were assayed for splicing activity by reverse-
transcription polymerase chain reaction (RT-PCR). Of these 21 morpholinos, 10 did not
result in any hematopoietic defect. For the 10, one gene could not be evaluated because no
PCR product was detected. Only one of the nine remaining morpholinos did not show
altered splicing activity, resulting in an estimated false negative rate (FNR) of 11% for the
screen (Supplementary Fig. 1a-b). To expand on this limited approach, we verified the
splicing activity of an additional 48 splice blocking morpholinos that scored negative in both
primitive and definitive screens. In total, 51 of 57 morpholinos caused altered splicing,
resulting in the same estimated FNR of 11%. Furthermore, the knock down efficiencies were
comparable to those that gave a hematopoietic defect (Supplementary Fig. 5).
Classification of screen results
Gene expression phenotypes observed in morpholino injected embryos, or morphants, were
classified into one of three major categories: no change, decrease, or increase. Due to the
range of decreased staining from subtle to complete absence of staining, we subdivided the
decrease category into mild, intermediate, and strong (Fig. 2a-b, Supplementary Table 2).
Any morphant showing changes in β-globin e3 or c-myb/runx1 expression was considered a
screen hit. Morphants with developmental abnormalities were listed separately
(Supplementary Fig. 2a-b, Supplementary Table 2). As morphologically normal morphants
with the strongest decrease or increase in blood formation represented genes that were likely
to be specific to blood development, these 26 primitive and 47 definitive factors were
selected for further characterization.
Chromatin factors regulate primitive blood development from the mesoderm
Of the 26 morphants with altered primitive erythropoiesis, knockdown of 13 chromatin
factors reduced β-globin e3 expression and 13 factors increased β-globin e3 expression at 16
ss. To confirm these phenotypes, we rescreened for β-globin e3 expression. 16 of the 26
genes were verified, 6 from the reduced group and 10 from the increased group
(Supplementary Table 3). Given that morpholinos can fail to inhibit their intended targets,
splicing activity was confirmed by RT-PCR for the ten splice blocking morpholinos used,
and a second, nonoverlapping morpholino was tested to verify the initial screen result for all
factors. 15 of the 16 genes were validated in this manner and characterized further (Fig. 3a-
b, Supplementary Fig. 5). To show that the morpholinos did not just affect globin
expression, one gene from each decrease category was reevaluated with a second erythroid
marker, band3. The decrease in band3 expression was consistent with the decrease in β-
globin e3 expression and was not rescued by p53 loss (Fig. 3c), suggesting minimal, if any,
morpholino toxicity. Overall, these additional tests provide further support for the validity of
the screen results.
To examine early hematopoietic defects during the formation of mesodermal precursors and
erythroid progenitors, we evaluated scl and gata1 expression at 10-12ss (14hpf),
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trespectively (Fig. 4)20. Of the 15 morphants tested, 12 showed changes in scl and gata1
expression consistent with the changes in β-globin e3, suggesting that most of the factors
categorized in the strong decrease or increase categories play a role in the formation of
mesodermal precursors competent to make blood. Knockdown of one factor in particular,
smarca1 (or snf2l), strikingly abrogated expression of all three markers, implicating a
requirement for this gene early in hematopoietic development (Supplementary Fig. 4a). The
remaining three, chrac1, actr2b, and hdac9b, had normal scl expression but reduced gata1
and β-globin e3 expression, indicating that these factors function to regulate the formation of
erythroid progenitors from the mesoderm (Fig. 4). The majority of these factors represent
previously unidentified regulators of erythroid development.
Chromatin factors regulate the induction of HSPCs
As in the primitive screen, we rescreened the 47 definitive genes (41 with a strong decrease
and 6 with increase runx1/c-myb expression) and confirmed 31 genes: 26 morphants
recapitulated the initial strong decrease in c-myb and runx1 expression in the AGM at 36
hpf, and 5 were verified for increased c-myb and runx1 expression (Supplementary Table 3).
For morphants in the decrease category, expression of both markers was nearly abolished in
the AGM. Morpholinos injected in a p53-/- background did not rescue the loss of expression
of AGM markers, indicating these phenotypes were not the result of morpholino toxicity
(Fig. 3d). To verify the efficacy of the morpholinos, splicing activity was assessed and
confirmed for all 21 splice blocking morpholinos used. 29 of the 31 genes were validated
with a second, nonoverlapping morpholino and selected for further characterization (Fig. 3a-
b, Supplementary Fig. 5). Collectively, these data provide additional verification of our
definitive screen data.
Previous work has shown that HSPCs emerge from the hemogenic endothelium of the dorsal
aorta and that proper vessel development and establishment of artery identity is necessary
for AGM stem cell induction23,24. The expression of vascular marker flk1 and arterial
identity marker ephrinB2 were analyzed for the 29 verified genes. The majority (20 of 29)
showed normal flk1 and ephrinB2 expression. While these results do not directly
demonstrate a cell autonomous mechanism, they do suggest that the chromatin factors
identified in the strong decrease and increase categories function in the specification or
maintenance of HSPCs from the hemogenic endothelium, as the tissues that arise most
proximal to HSC specification were intact (Fig. 5). Both known stem cell regulators, such as
hdac1 and prdm16, and unknown factors, including brd8a, cbx6b, jmjd1c, and nap1l4a,
were identified11,24.
The remaining ten chromatin factors were found to function at earlier stages of vessel
specification based on the presence of vascular defects. Four of the factors, hdac4l, mbd3b,
phf21a, and suv39h1, showed normal flk1 levels but reduced ephrinB2 expression,
suggesting they function in the establishment of aorta identity upstream of HSPC formation .
Finally, 5 morphants, mier1, jhdm1bb, jmjd1ca, ing4, and rbbp7, lost both intersomitic flk1
and arterial ephrinB2 expression, hence the loss of HSPCs in these morphants is likely due
to the absence of hemogenic endothelium. Overall, our definitive screen uncovered
chromatin regulators involved in the development of HSPCs from the AGM and during
vascular development.
Genes associated with mild to moderate knockdown phenotypes are important regulators
of hematopoietic development
In addition to chromatin factors with strong decrease or increase phenotypes, other factors
with moderate to mild phenotypes also function in hematopoietic development.
(Supplementary Table 3). We characterized seven genes from the primitive screen that
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tshowed only an intermediate reduction in β-globin e3 expression upon reinjection. Of these
seven morphants, six had normal scl but reduced gata1 expression, suggesting that they
likely function at the erythroid specification stage. Two of these factors, CHD4 and CBX8,
associate with the FOG1/GATA1 transcriptional complex and the TIF1-γ elongation
complex, respectively; both complexes are key regulators of erythroid development25,26.
Finally, kat5 showed a decrease in β-globin e3 without loss of scl and gata1 expression,
indicating it plays a role in erythroid cell differentiation. In comparison to the 15 genes with
the strongest phenotypes, those with more mild phenotypes likely function at later stages of
erythropoiesis after induction of the scl+ mesoderm.
Similarly, for genes with moderate phenotypes from the definitive screen, we did not
observe any defects in flk1 and ephrinB2 expression for 10 definitive morphants that were
reconfirmed in the intermediate decrease category, suggesting these genes also regulate
HSPC development. In summary, our screen has identified a large number of chromatin
factors that contribute to different stages of primitive and definitive hematopoiesis.
A chromatin factor interaction network for hematopoietic cell development
Given that chromatin factors often function in multisubunit complexes, we sought to identify
complexes important for hematopoietic development by mapping known protein interactions
for the genes identified in our screen. We started by annotating the protein complexes for the
44 validated genes from the primitive and definitive screens and included additional genes
from the screen that were also present in these complexes27. Our results implicate multiple
chromatin factor complexes required for developmental hematopoiesis: BAF/PBAF and
ISWI (chromatin remodeling), SET1 (histone methylation - activation), HDAC/NuRD
(histone deacetylation), NuA4/P300/CBP/HBO1 (histone acetylation), and PRC1/2 (histone
methylation - repression) (Fig. 6, Supplementary Fig. 3).
To identify all possible chromatin complexes represented by our screen datasets, we
generated a human protein-protein interaction map of the 425 chromatin factors screened
and mapped the factors found in our screen (102 primitive and 116 definitive factors) onto
the network. We identified the same complexes as we did in the previous analysis with the
addition of a ubiquitination complex (Fig. 7, Supplementary Fig. 3).
As chromatin factors associated with the same complex likely share target binding sites, we
analyzed 34 published ChIP-seq (chromatin immunoprecipitation followed by sequencing)
datasets in K562 erythroleukemia cells of chromatin factors in our screen28. Two major
complexes were found. The first group includes SIN3A, CHD4, HDAC1, TAF1, and
JARID1C associated with the HDAC/NuRD complex, and the second group includes RNF2,
SUZ12, CBX2, and CBX8 from the Polycomb complexes. We ranked triplet combinations
of these factors together with all other groups of three factors based on the percent overlap
of target genes. The HDAC/NuRD and PRC1/2 complex combinations predicted from our
screen, including those which have been shown to interact biochemically, fell within the top
20% of all possible combinations of three factors (Supplementary Fig. 4a,c). After excluding
a subset often factors that have large target gene lists (>8,000 target genes), which could
skew the distribution, this filtered analysis resulted in the predicted interactions falling
within the top 5% of all combinations (Supplementary Fig. 4b,c). Both predicted interactions
are significantly enriched in the upper tail of the distribution in the two analyses, therefore
suggesting that our screen has identified chromatin factors that function in distinct
complexes to regulate hematopoietic development.
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Based on complexes identified, we expected that chromatin factor subunits that scored
positive in our screen would interact genetically. We tested the interaction by combinatorial
knockdown of ISWI subunits required for primitive erythropoiesis, smarca1, chrac1, and
rsf1b (Fig. 6)29,30. As described in the previous section, loss of these factors individually
resulted in decreased gata1 and β-globin e3 expression. Knockdown of smarca1 and rsf1b
also reduced scl expression. In knocking down all three factors at suboptimal doses, scl
expression is retained while gata1 and β-globin e3 expression is highly reduced as in the
single morphants (Fig. 8a). In contrast, knockdown of SWI/SNF components brg1, baf57,
and baf170, which were not identified as primitive screen hits, did not result in primitive
hematopoietic defects individually or in combination (Fig. 8b)31,32. These data suggest that
the chromatin factors we identified from our screen interact genetically to regulate
hematopoietic development.
Discussion
Hematopoietic stem cells undergo proliferation and differentiation under the control of cell-
specific transcription factors whose function is facilitated by chromatin factors. These
factors establish an epigenetic landscape that controls self-renewal and provides lineage
priming, driving differentiation. To better understand the epigenetic regulation of the
hematopoiesis, we undertook the first reverse genetic approach to define the function of
chromatin factors in the zebrafish. A library of zebrafish genes orthologous to 425 human
chromatin factors were identified, containing canonical ‘readers’, ‘writers’, and ‘erasers’ of
chromatin and other, less characterized, families.
In this study, we characterized a cohort of 15 chromatin factors that regulate primitive
hematopoiesis and 29 that regulate definitive hematopoiesis, including both known and
previously unidentified factors. Based on our validation work, the data suggest that these
factors function at the level of erythroid and HSPC specification. Our analysis of several
blood-specific markers at several distinct timepoints has been used to describe
differentiation defects in many zebrafish blood mutants33,34. However, a delay in blood
development would also readout as a decrease phenotype. As well, it is possible that an
accelerated emergence of blood cells could confound our analysis except when it results in
an overall increase in blood production. Regardless of whether blood development is
selectively delayed or accelerated, our results ultimately show expression of the blood
markers is altered, whether directly or indirectly affecting any number of pathways, such as
metabolism, transcriptional elongation, and cell cycle regulation. Additional work will be
required to determine the mechanism of action on hematopoiesis and whether these
phenotypes are cell autonomous.
Disruption of both positive and negative regulators of chromatin frequently resulted in the
same phenotype in our screen. For example, knockdown of p300, which functions to
acetylate histones, and hdac6, which deacetylates histones, each resulted in loss of c-myb+
and runx1+ cells in the AGM. While they likely serve opposing roles in regulation of their
respective target genes, their functions are both required for proper HSC specification.
These data are in concordance with proteomics data showing transcription factors, such as
GATA1, recruiting both positive and negative regulators to activate and repress target genes,
respectively35.
While members of the same chromatin family could compensate for each other, individual
knockdown of many of these factors still resulted in a hematopoietic phenotype, suggesting
nonredundant functions among related chromatin factors. Two factors that were identified
from our screen, p300 and crebbp, share similar functions but showed opposing phenotypes.
Huang et al. Page 6
Nat Cell Biol. Author manuscript; available in PMC 2014 June 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tp300 and CBP are homologous proteins that share a bromodomain and histone
acetyltransferase domain36. Mouse knockouts of p300 and Cbp exhibit similar
phenotypes37. Despite their overlapping roles, evidence of differential regulation has been
accumulating. In HSCs, Cbp plays an important role in HSC self-renewal whereas p300
regulates HSC differentiation. Recent ChIP-seq results identified distinct binding sites
between the two factors38,39. Consequently, the effect chromatin factors have in vivo cannot
be predicted based solely on their domain function. Future in vivo studies will be important
for our understanding of chromatin regulation and gene expression.
In a recent study investigating histone modifications on differentiating erythroid cells in
mouse fetal liver, five histone marks were induced during this transition, H3K4me2,
H3K4me3, H3K9Ac, H4K16Ac, and H3K79me240. Consistent with these findings, our
strongest primitive hits are composed of chromatin factors involved in methylation and
acetylation of histones, including H3K4 methylation. Although similar work characterizing
changes in histone marks during various stages of definitive HSC formation has not been
done, we predict that they will include histone modifications such as methylation of H3K4,
H3K9, and H3K36 based on the chromatin factors identified in our screen.
By examining our screen results, we identified relevant chromatin modifying complexes for
blood development including BAF/PBAF, ISWI, HDAC/NuRD, NuA4/P300/CBP/HBO1,
SET1, and PRC1/2 complexes. Hypotheses regarding the subunit composition of the
chromatin factor complexes can be generated using our data set. One of the most striking
results from our primitive screen was the knockdown of smarca1, which abrogates scl,
gata1, and β-globin e3 expression in the embryo. chrac1 and rsf1b, other components that
form the ISWI complex, were also identified in the screen. In mammalian data, these factors
form a complex with another family member, smarca5. Our data suggests that ISWI
chromatin remodeling is important for primitive and definitive hematopoiesis and that the
complex contains smarca1 (not smarca5), chrac1, and rsf1b. As well, by comparing
chromatin occupancy of complex members, we observed higher proportions of bound genes
among factors predicted to be in the same complex. Taken together, these data suggest that
our screen has identified chromatin factors that function in distinct complexes to regulate
hematopoiesis.
Overall, we have identified a set of genes involved in the regulation of developmental
hematopoiesis, including primitive erythropoiesis and definitive HSPC specification, and
provide a resource for the identification and characterization of previously unidentified
regulators. Studies focusing on the interactions between hematopoietic transcription factors
and our chromatin factors will provide a more complete transcriptional network of gene
regulation in blood development. In combination with other genetic and biochemical studies,
our screen helps to unravel the epigenetic code that establishes the programs of gene
expression for self-renewal and differentiation in hematopoietic cells.
Supplementary Material
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Screen design for chromatin regulators of developmental hematopoiesis. (a) Schematic
illustration of screening procedure. Knockdown of 488 zebrafish orthologs of 425 human
chromatin factors was achieved using morpholinos. Embryos were subsequently collected at
17 hpf and 36 hpf to analyze changes in β-globin e3 expression in primitive erythroid cells
and c-myb and runx1 expression in definitive HSPCs, respectively, by WISH. (b) Example
of primitive screen phenotype observed for reduced β-globin e3 expression at 17 hpf. (c)
Example of definitive screen phenotype observed for reduced c-myb and runx1 expression at
36 hpf. Scale bars: 100μm for low magnification and 25 μm for high magnification.
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Classification of screen results. (a) Summary of primitive screen WISH results. Developing
β-globin e3+ erythroid cells are found as two bilateral stripes in the posterior of the embryo,
as shown by the red highlights in the schematic of a 16 ss embryo. Knockdown of the
different chromatin factors resulted in no change, decrease, or increase of β-globin e3
expression. (b) Summary of definitive screen WISH results. Induction of c-myb+ and runx1+
HSPCs occurs in the AGM region highlighted in red in the schematic of a 36 hpf embryo.
Knockdown of the different chromatin factors screened resulted in no change, decrease, or
increase of c-myb and runx1 expression. Representative WISH results are shown for each
phenotypic category with additional categories continued in Supplementary Fig. 2. “n” is the
number of chromatin factors with the indicated phenotype. Blue downward arrows represent
reduced marker expression and magenta upward arrows represent increased marker
expression. One arrow indicates a mild change, two arrows an intermediate change, and
three arrows a strong change. Scale bars: 100μm
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tFigure 3.
Morpholino efficacy and secondary verification of screen phenotypes. (a) Flow chart of
screening morpholino validation procedure. 44 of the 48 genes identified from the screen
were verified with a second, nonoverlapping morpholino. The remaining 4 were
recategorized. Splicing activity for splice blocking morpholinos were assayed and confirmed
by RT-PCR for the 31 primary screen morpholinos and the 4 secondary morpholinos that
did not phenocopy the primary screen results. n = is the number of morpholinos under each
category. (b) Example of primitive and definitive screen hits that were verified with a
secondary morpholino and show splicing activity by RT-PCR. ef1α was used as the control
gene. Arrowheads mark the presence of a PCR band. Filled in arrowheads indicate wild-type
bands and empty arrowheads indicate spliced bands. w.t stands for wild-type. (c) A subset of
3 primitive genes that resulted in decreased globin expression when knocked down were
selected, one from each decrease category, to test for expression of a second erythroid
marker, band3.(d) A subset of 3 definitive genes that resulted in decreased c-myb and runx1
expression when knocked down were selected, one from each category shown in Fig. 5.
Given that two probes were used during the screen and expression of both genes were nearly
abolished in the morphants, only the p53-/- rescue experiment was performed. n.a. stands for
not applicable. Scale bars: 100μm for low magnification and 25 μm for high magnification.
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Chromatin factors regulate distinct steps of primitive erythroid development. 15 primitive
genes were screened for changes in scl expression marking hematopoietic mesodermal
precursors (yellow highlight) and gata1 expression marking erythroid progenitor formation
(orange highlight) illustrated in the top panel (flatmount view). β-globin e3 staining was
repeated to verify primary screen results (posterior view). myoD probe for labeling somites
was included as a staging marker. Blue downward arrow represents reduced expression.
Magenta upward arrow represents increased expression. A hyphen indicates no change in
gene expression. Square brackets indicate the thickness of the stripes. Scale bar: 100μm
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Chromatin factors regulate distinct steps of definitive HSPC development. 29 definitive
genes were screened for changes in flk1 expression marking the vessels (tan highlight) and
ephrinB2 expression marking the artery endothelium (purple highlight) illustrated in the top
panel. c-myb and runx1 staining was repeated to verify primary screen results. Blue
downward arrow represents reduced expression. Magenta upward arrow represents
increased expression. A hyphen indicates no change in gene expression. Scale bars: 100μm
for low magnification and 25 μm for high magnification.
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Identification of chromatin modifying complexes using protein interaction data for the 44
validated primitive and definitive genes. Protein complexes associated with the 44
chromatin factors from the decrease (strong) and increase categories were identified, and
additional genes from the screen present in these complexes were included (Uniprot).
Results for SWI/SNF, ISWI, SET1, and CBP/P300 are illustrated with additional complexes
shown in Supplementary Figure 3. Filled in circles represent chromatin factors that were
identified as screen hits with their respective phenotypic classification denoted by different
colors. Dotted lines indicate alternative complex associations.
Huang et al. Page 16
Nat Cell Biol. Author manuscript; available in PMC 2014 June 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 7.
A protein-protein interaction network for the 425 human chromatin factors screened. Screen
results for 102 primitive and 116 definitive genes were mapped onto the network, and highly
interconnected modules containing factors identified from the screens were isolated,
representing the chromatin complexes important for hematopoietic development39. Detailed
maps of the modules are in Supplementary Figure 5. Each module is assigned a unique
color, and those that share the same chromatin function are highlighted in the same
background color. Grey circles represent chromatin factors not associated with the isolated
complexes, and white circles mark additional factors that were added to increase the
connectivity of the network.
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Genetic interaction of ISWI chromatin factors by combinatorial knockdown. (a) gata1 and
β-globin e3 expression levels were examined by injecting single and combined suboptimal
doses of morpholinos against smarca1, chrac1, and rsf1b. Combined dose of 7.5 ng includes
4 ng of smarca1, 0.8 ng of chrac1, and 2.7 ng of rsf1b.(b) Knockdown of SWI/SNF
chromatin factors baf57, baf170, and brg1, which were not identified as hits from the screen,
were tested for β-globin e3 expression either individually or in combination. Combined dose
of 12 ng includes 4 ng of each of the three morpholinos. Morpholino doses are indicated as
nanograms (ng). Scale bars: 100μm
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